Michael Deluca, MD
Interventional Cardiology · El Paso, TXNPI 1053311936
Payments from drug & device makers
Across 451 payments — averaging $44.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$11K
- Abbott$3K
- Boston Scientific$879
- Medtronic$828
- Johnson & Johnson$762
- AstraZeneca$631
- plus $3K from 22 others
What the payments were for
- Consulting fees$4,50022%
- Speaking & faculty fees$4,75023%
- Travel & lodging$7494%
- Food & beverage$10,15950%
- Education$840%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 46 | $11,220 |
| Abbott | 47 | $2,700 |
| Boston Scientific | 58 | $879 |
| Medtronic(2 entities) | 24 | $828 |
| Johnson & Johnson | 62 | $762 |
| AstraZeneca | 31 | $631 |
| Novartis | 39 | $607 |
| E.r. Squibb & Sons, L.L.C. | 43 | $566 |
| Pfizer | 24 | $378 |
| Amgen | 22 | $343 |
| Boehringer Ingelheim | 16 | $284 |
| Terumo Medical Corporation | 5 | $278 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $201 |
| Philips North America LLC | 3 | $101 |
| Novo Nordisk | 3 | $68 |
| Merck | 4 | $58 |
| Shockwave Medical, Inc | 2 | $42 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 3 | $41 |
| W. L. Gore & Associates, Inc. | 2 | $39 |
| Cordis US CORP. | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $33 |
| Tactile Systems Technology Inc | 2 | $27 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Heartflow, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUTONIX$4,647
- VENOVO$968
- Allure Quadra RF CRT Pacemaker$280
- Quadra Assura CRT Defibrillator$280
- HawkOne$188
- Confirm Rx$150
- Quadra Allure MP RF CRT Pacemkr$115
- HeartMate 3 Left Ventricular Dev$115
- Durata Defibrillation ICD Lead$109
- Navicross$105
- AZUR$105
- MetaCross$105
- RESOLUTE ONYX$104
- Quartet CRT Lead$103
- BRILINTA$103
- FARXIGA$103
How this compares
$20,241 in reported general payments places this provider in the 65th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 497 | $606,822 |
| XareltoRivaroxaban | 240 | $299,543 |
| BrilintaTicagrelor | 57 | $54,021 |
| EntrestoSacubitril/Valsartan | 36 | $46,695 |
| MultaqDronedarone Hcl | 14 | $22,498 |
| Repatha SureclickEvolocumab | 14 | $11,480 |
| Metoprolol Succinate | 790 | $9,323 |
| Carvedilol | 978 | $8,672 |
| Ranolazine ErRanolazine | 60 | $7,050 |
| Losartan Potassium | 575 | $6,001 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 527 | $5,758 |
| ClopidogrelClopidogrel Bisulfate | 486 | $5,336 |
| SotalolSotalol Hcl | 197 | $5,024 |
| Flecainide Acetate | 136 | $5,020 |
| Nisoldipine | 14 | $4,750 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $378 | $606,822497 claims |
| Johnson & JohnsonXarelto | $762 | $299,543240 claims |
| AstraZenecaBrilinta | $631 | $54,02157 claims |
| NovartisEntresto | $607 | $46,69536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in El Paso
- Mohammad RajaEl Paso$319K
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.